Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

379 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Effects of the angiotensin-receptor blocker telmisartan on cardiovascular events in high-risk patients intolerant to angiotensin-converting enzyme inhibitors: a randomised controlled trial.
Telmisartan Randomised AssessmeNt Study in ACE iNtolerant subjects with cardiovascular Disease (TRANSCEND) Investigators; Yusuf S, Teo K, Anderson C, Pogue J, Dyal L, Copland I, Schumacher H, Dagenais G, Sleight P. Telmisartan Randomised AssessmeNt Study in ACE iNtolerant subjects with cardiovascular Disease (TRANSCEND) Investigators, et al. Among authors: pogue j. Lancet. 2008 Sep 27;372(9644):1174-83. doi: 10.1016/S0140-6736(08)61242-8. Epub 2008 Aug 29. Lancet. 2008. PMID: 18757085 Clinical Trial.
Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients.
Heart Outcomes Prevention Evaluation Study Investigators; Yusuf S, Sleight P, Pogue J, Bosch J, Davies R, Dagenais G. Heart Outcomes Prevention Evaluation Study Investigators, et al. Among authors: pogue j. N Engl J Med. 2000 Jan 20;342(3):145-53. doi: 10.1056/NEJM200001203420301. N Engl J Med. 2000. PMID: 10639539 Free article. Clinical Trial.
Blood-pressure reduction and cardiovascular risk in HOPE study.
Sleight P, Yusuf S, Pogue J, Tsuyuki R, Diaz R, Probstfield J; Heart Outcomes Prevention Evaluation (HOPE) Study. Sleight P, et al. Among authors: pogue j. Lancet. 2001 Dec 22-29;358(9299):2130-1. doi: 10.1016/S0140-6736(01)07186-0. Lancet. 2001. PMID: 11784631
Vitamin E supplementation and cardiovascular events in high-risk patients.
Heart Outcomes Prevention Evaluation Study Investigators; Yusuf S, Dagenais G, Pogue J, Bosch J, Sleight P. Heart Outcomes Prevention Evaluation Study Investigators, et al. Among authors: pogue j. N Engl J Med. 2000 Jan 20;342(3):154-60. doi: 10.1056/NEJM200001203420302. N Engl J Med. 2000. PMID: 10639540 Free article. Clinical Trial.
Meta-analysis.
Yusuf S, Pogue J. Yusuf S, et al. Among authors: pogue j. Lancet. 1998 Jun 27;351(9120):1960. doi: 10.1016/S0140-6736(05)78646-3. Lancet. 1998. PMID: 9654288 No abstract available.
Reduction of cardiovascular risk by regression of electrocardiographic markers of left ventricular hypertrophy by the angiotensin-converting enzyme inhibitor ramipril.
Mathew J, Sleight P, Lonn E, Johnstone D, Pogue J, Yi Q, Bosch J, Sussex B, Probstfield J, Yusuf S; Heart Outcomes Prevention Evaluation (HOPE) Investigators. Mathew J, et al. Among authors: pogue j. Circulation. 2001 Oct 2;104(14):1615-21. doi: 10.1161/hc3901.096700. Circulation. 2001. PMID: 11581138 Clinical Trial.
Effect of rosiglitazone on the frequency of diabetes in patients with impaired glucose tolerance or impaired fasting glucose: a randomised controlled trial.
DREAM (Diabetes REduction Assessment with ramipril and rosiglitazone Medication) Trial Investigators; Gerstein HC, Yusuf S, Bosch J, Pogue J, Sheridan P, Dinccag N, Hanefeld M, Hoogwerf B, Laakso M, Mohan V, Shaw J, Zinman B, Holman RR. DREAM (Diabetes REduction Assessment with ramipril and rosiglitazone Medication) Trial Investigators, et al. Among authors: pogue j. Lancet. 2006 Sep 23;368(9541):1096-105. doi: 10.1016/S0140-6736(06)69420-8. Lancet. 2006. PMID: 16997664 Free article. Clinical Trial.
Long-term ACE-inhibitor therapy in patients with heart failure or left-ventricular dysfunction: a systematic overview of data from individual patients. ACE-Inhibitor Myocardial Infarction Collaborative Group.
Flather MD, Yusuf S, Køber L, Pfeffer M, Hall A, Murray G, Torp-Pedersen C, Ball S, Pogue J, Moyé L, Braunwald E. Flather MD, et al. Among authors: pogue j. Lancet. 2000 May 6;355(9215):1575-81. doi: 10.1016/s0140-6736(00)02212-1. Lancet. 2000. PMID: 10821360
Clopidogrel plus aspirin versus oral anticoagulation for atrial fibrillation in the Atrial fibrillation Clopidogrel Trial with Irbesartan for prevention of Vascular Events (ACTIVE W): a randomised controlled trial.
ACTIVE Writing Group of the ACTIVE Investigators; Connolly S, Pogue J, Hart R, Pfeffer M, Hohnloser S, Chrolavicius S, Pfeffer M, Hohnloser S, Yusuf S. ACTIVE Writing Group of the ACTIVE Investigators, et al. Among authors: pogue j. Lancet. 2006 Jun 10;367(9526):1903-12. doi: 10.1016/S0140-6736(06)68845-4. Lancet. 2006. PMID: 16765759 Clinical Trial.
379 results